Clinical trials: Glaucoma, Open-Angle
Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma
Safety and tolerability of three different concentrations (0.1%, 03%, 0.6%) of the investigational SHP639 eye drops will be evaluated in participants with high eye pressure or primary open-angle glaucoma.
- Trial name
- NCT03131167
- Testing
- SHP639 (n=60)
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Shire
Ocular Hypertension, Open-Angle Glaucoma
Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops
The purpose of this study is to investigate if changes in ocular signs and symptoms occur in patients with ocular hypertension or glaucoma when they switch from latanoprost 0.005% (Xalatan) to preservative free Tafluprost eye…
- Trial name
- NCT01087671
- Testing
- tafluprost
- Volunteers
- 185 people
- Sponsor
- Santen Oy
Open-Angle Glaucoma or Ocular Hypertension, Ocular Surface Disease
A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension
A Phase III, Multinational, Multicenter, Investigator-Masked, Randomized, Active-Controlled Trial, comparing the efficacy and safety of DE-130A with Xalatan® in Patients with Open-Angle Glaucoma or Ocular Hypertension over a…
- Trial name
- NCT04133311
- Testing
- DE-130A, Xalatan®, DE-130A/DE-130A
- Where
- France
- Volunteers
- 386 people
- Sponsor
- Santen SAS
Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
The goal of this clinical trial is to evaluate the safety and tolerability of a single dose of ER-100 in adults with optic nerve conditions, specifically Open Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic…
- Trial name
- NCT07290244
- Testing
- ER-100 epigenetic therapy
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Life Biosciences Inc.
Myopia, Refractive Errors
Effect of Peripapillary Atrophy to Diagnose Glaucoma in High Myopia
This study intends to analyze the characteristics between peripapillary retinal nerve fiber layer thickness and peripapillary area in high myopia with or without glaucoma
- Conditions
- Myopia, Refractive Errors, Eye Diseases, Glaucoma, Primary Open Angle
- Trial name
- NCT05964634
- Testing
- OCT imaging
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Glaucoma
Comparison Of Trabeculectomy Versus The Ex-PRESS Miniature Glaucoma Device In The Same Patient: A Prospective Randomized Study
the purpose of this study was to compare standard trabeculectomy to the Ex-PRESS mini glaucoma shunt implantation under a scleral flap in eyes with open-angle glaucoma.In this report, we describe the results of a prospective…
- Trial name
- XVT-USF (NCT00698438)
- Testing
- Ex-PRESS implantation, Trabeculectomy
- Where
- South Africa
- Volunteers
- 30 people
- Sponsor
- University of Witwatersrand, South Africa
Open-Angle Glaucoma
Collection of Blood Specimens From Patients in AL-3789 Studies for Elevated Intraocular Pressure (IOP)
The objective of this study is to obtain blood samples from patients who are or were participants in any Alcon AL-3789 clinical trial.
- Trial name
- NCT00691639
- Testing
- Blood Collection Only
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Alcon Research
Open Angle Glaucoma, Ocular Hypertension
Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan
Test ocular hypotensive efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan
- Trial name
- NCT03844945
- Testing
- Netarsudil Ophthalmic Solution 0.01%, Netarsudil Ophthalmic Solution 0.02%, Netarsudil Ophthalmic Solution 0.04%
- Where
- 25 sites in Japan
- Volunteers
- 215 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma, Cataract
Evaluation of Microinvasive Glaucoma Surgery: MINIject® Versus Hydrus® Microstent in Combination With Cataract Surgery
The study aims to investigate postoperative outcomes after two different MIGS implants (MINIject or Hydrus) in combination with cataract surgery for patients with glaucoma.
- Trial name
- MINHY (NCT06844292)
- Testing
- MINIject with Cataract Surgery, Hydrus Microstent with Cataract Surgery
- Where
- Austria
- Volunteers
- 152 people
- Sponsor
- Medical University of Graz
Open-angle Glaucoma, Ocular Hypertension
Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients
The purpose of this study is to determine the safety and IOP-lowering ability of a glaucoma therapy in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00069706
- Testing
- AL-12182 0.003% Ophthalmic Solution, AL-12182 Ophthalmic Solution Vehicle, Latanoprost 0.005% Ophthalmic Solution
- Volunteers
- 118 people
- Sponsor
- Alcon Research
Open-angle Glaucoma (OAG)
5-Year Postoperative Outcomes of Patients Who Completed the CREST Study
This study is designed to collect clinical data at 3, 4, and 5 years postoperatively for participants who completed the CREST Study without having secondary IOP-lowering surgery in the study eye(s).
- Trial name
- CREST-XT (NCT07480343)
- Testing
- CycloPen Micro-Interventional Cyclodialysis System, CycloPen Micro-Interventional Cyclodialysis System Post Cataract
- Where
- 10 sites in United States
- Volunteers
- 250 people
- Sponsor
- Iantrek, Inc.
Glaucoma, Open Angle, Ocular Hypertension
A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma
To demonstrate the statistical non inferiority of the combination of latanoprost and timolol given in the evening time once a day vs the combination of dorzamalide and timolol twice a day based on intraocular pressure…
- Trial name
- NCT00140049
- Testing
- Xalacom, Cosopt
- Where
- 25 sites in France, Germany and 3 more
- Volunteers
- 238 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma
Predicting the Effect of Laser Peripheral Iridotomy
This study will compare the angle parameters of patients with PACS before and after LPI. The investigators will analyze the results of patients with different angle closure mechanisms before and after LPI, and participants hope…
- Trial name
- NCT04495491
- Testing
- pupillary block group, plateau iris group, mixing mechanism group
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Open Angle Glaucoma, Ocular Hypertension
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma.
- Trial name
- Denali (NCT04630808)
- Testing
- NCX 470 0.1%, Latanoprost 0.005%
- Where
- 88 sites in United States, China
- Volunteers
- 696 people
- Sponsor
- Nicox Ophthalmics, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Corneal Versus Conjunctival Delivery Using a Delivery Device
Compare the antihypertensive efficacy of three methods for installing Xalatan
- Trial name
- NCT00143429
- Testing
- Xalatan
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open-Angle Glaucoma, Ocular Hypertension
Latanoprost Versus Fotil
To compare the intraocular pressure effect and safety of latanoprost 0.005% given every evening versus PTFC given twice daily.
- Trial name
- NCT00304785
- Testing
- latanoprost 0.005%, Fotil
- Where
- 5 sites in Poland
- Volunteers
- 36 people
- Sponsor
- Pharmaceutical Research Network
Open Angle Glaucoma, Ocular Hypertension
The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure
The purpose of this research study is to hypothesize that Simbrinza will achieve a decrease in intraocular pressure and increase in ocular perfusion pressure throughout the diurnal and nocturnal periods.
- Conditions
- Open Angle Glaucoma, Ocular Hypertension, Pigment Dispersion Syndrome, Pseudoexfoliation Glaucoma
- Trial name
- NCT02165631
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Colorado, Denver
Ocular Hypertension, Primary Open-angle Glaucoma
BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension
The purpose of this study is to evaluate the clinical efficacy of the BREMEN eye drops in the treatment of primary open-angle glaucoma or intraocular hypertension.
- Trial name
- NCT03235232
- Testing
- BREMEN eye drops, Combigan®
- Where
- Brazil
- Volunteers
- 406 people
- Sponsor
- EMS
Primary Open-angle Glaucoma
Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment
The purpose of this study is to develop an educational program that will help improve the patients' understanding of what laser treatment is, how it might be beneficial to them, and why it should be the first eye pressure…
- Trial name
- NCT03365778
- Testing
- Patient Educational Intervention, Usual Care, Ophthalmologist Educational Intervention
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Wills Eye
Primary Open Angle Glaucoma
Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket Cohort
The purpose of this study is to assess the long-term safety of the Glaukos® iStent® Trabecular Micro-Bypass Stent Model GTS100R/L in subjects previously enrolled in Glaukos Study GC-003.
- Trial name
- NCT01836042
- Where
- 26 sites in United States
- Volunteers
- 108 people
- Sponsor
- Glaukos Corporation